FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / J Vet Intern Med / Time-dependent antiarrhythmic effects of flecainide on induc...
Journal of veterinary internal medicine2018; 32(5); 1708-1717; doi: 10.1111/jvim.15287

Time-dependent antiarrhythmic effects of flecainide on induced atrial fibrillation in horses.

Abstract: Pharmacological treatment of atrial fibrillation (AF) in horses can be challenging because of low efficacy and adverse effects. Flecainide has been tested with variable efficacy. Objective: To test whether the efficacy of flecainide is dependent on AF duration. Methods: Nine Standardbred mares. Methods: Factorial study design. All horses were instrumented with a pacemaker and assigned to a control or an AF group. On day 0, all horses were in sinus rhythm and received 2 mg/kg flecainide IV. Atrial fibrillation subsequently was induced in the AF group by pacemaker stimulation. On days 3, 9, 27, and 55, flecainide was administered to all horses, regardless of heart rhythm. Results: All horses in AF cardioverted to sinus rhythm on days 3 and 9. On day 27, 5/6 horses cardioverted, whereas only 2/6 cardioverted on day 55. The time from the start of flecainide infusion to cardioversion (range, 3-185 min, log transformed) showed linear correlation with the cumulative duration of AF (r2  = .80, P < .0001). Flecainide induced abnormal QRS complexes in 4/6 AF horses and 1/3 controls. A positive correlation was found between heart rate before flecainide infusion and number of abnormal QRS complexes (0.14, P < .05). One horse suffered from cardiac arrest and died after flecainide infusion. Conclusions: Flecainide is effective for cardioversion of short-term induced AF, but the effect decreases with AF duration. Controlling heart rate may minimize adverse effects caused by flecainide, but the drug should be used with great caution.
© 2018 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.
Get Full Text
Publication Date: 2018-08-22 PubMed ID: 30133839PubMed Central: PMC6189357DOI: 10.1111/jvim.15287Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Clinical Trial
  • Veterinary
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research paper investigates the effectiveness of the drug flecainide in treating atrial fibrillation (AF) in horses, examining how treatment efficacy changes over time. The study concludes that while flecainide is effective for the short-term treatment of induced AF, its effectiveness decreases the longer the AF persists.

Objectives and Research Design

  • The scientists wanted to understand whether the efficacy of using the drug flecainide to treat atrial fibrillation (AF), a common heart disorder observed in horses, is affected by the duration of the condition.
  • They used a factorial study on nine Standardbred mares, splitting the horses into a control group and an AF group. Starting from a healthy state (sinus rhythm), the horses were treated with a dose of flecainide. AF was then induced in the AF group by using a pacemaker, after which flecainide was administered to all horses on various days regardless of their heart rhythm condition.

Results and Observations

  • On days 3 and 9, all AF horses were successfully converted back to sinus rhythm. However, by day 27, only 5 out of the 6 AF horses converted, and by day 55, only 2 out of 6 had converted.
  • A noted observation was that the time taken from flecainide infusion to conversion back to sinus rhythm increased linearly with the cumulative duration of AF. This suggests that the longer the horse had AF, the longer it took for flecainide to treat it.
  • Four of the six horses with AF and one of the three controls exhibited abnormal QRS complexes (a term describing certain findings on an electrocardiogram) after flecainide administration. There was a positive correlation between the heart rate before flecainide treatment and the number of abnormal QRS complexes observed.
  • One horse suffered a cardiac arrest and unfortunately died after flecainide administration, showcasing the need for cautious use of the drug.

Conclusion and Recommendations

  • According to the findings of the study, flecainide appears to be effective for the treatment of short-term induced AF. However, its effectiveness lessens as the duration of AF increases.
  • The authors suggest that controlling the horse’s heart rate might help minimize the potential adverse effects caused by flecainide. They also caution that the medication should be used very carefully considering the reported cardiac event in one horse.

Cite This Article

APA
Carstensen H, Hesselkilde EZ, Fenner M, Loft-Andersen AV, Flethøj M, Kanters JK, Sattler SM, Tfelt-Hansen J, Pehrson S, Jespersen T, Buhl R. (2018). Time-dependent antiarrhythmic effects of flecainide on induced atrial fibrillation in horses. J Vet Intern Med, 32(5), 1708-1717. https://doi.org/10.1111/jvim.15287

Publication

Journal of veterinary internal medicine
ISSN: 1939-1676
NlmUniqueID: 8708660
Country: United States
Language: English
Volume: 32
Issue: 5
Pages: 1708-1717

Researcher Affiliations

Carstensen, Helena
  • Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Taastrup, Denmark.
Hesselkilde, Eva Z
  • Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Taastrup, Denmark.
Fenner, Merle
  • Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Taastrup, Denmark.
Loft-Andersen, Ameli V
  • Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Taastrup, Denmark.
Flethøj, Mette
  • Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Taastrup, Denmark.
Kanters, Jørgen K
  • Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, København, Denmark.
Sattler, Stefan M
  • Department of Cardiology, The Heart Centre, Copenhagen University Hospital, København, Denmark.
  • Department of Medicine I, University Hospital Munich, Campus Grosshadern, Ludwig-Maximilians University Munich (LMU), Munich, Germany.
Tfelt-Hansen, Jacob
  • Department of Cardiology, The Heart Centre, Copenhagen University Hospital, København, Denmark.
  • Department of Forensic Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, København, Denmark.
Pehrson, Steen
  • Department of Cardiology, The Heart Centre, Copenhagen University Hospital, København, Denmark.
Jespersen, Thomas
  • Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, København, Denmark.
Buhl, Rikke
  • Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Taastrup, Denmark.

MeSH Terms

  • Animals
  • Anti-Arrhythmia Agents / therapeutic use
  • Atrial Fibrillation / drug therapy
  • Atrial Fibrillation / veterinary
  • Female
  • Flecainide / therapeutic use
  • Horse Diseases / drug therapy
  • Horses
  • Pacemaker, Artificial
  • Time Factors

Grant Funding

  • Marie Sklodowska-Curie grant agreement No 675351 / European Union Horizon 2020 research and innovation programme
  • 14-4713 / The Augustinus Foundation
  • 14-4713 / The Kustos Foundation of 1881

References

This article includes 43 references
  1. Reef VB, Bonagura J, Buhl R. Recommendations for management of equine athletes with cardiovascular abnormalities.. J Vet Intern Med 2014;28:749‐761.
    pmc: PMC4895474pubmed: 24628586
  2. Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation.. Cardiovasc Res 2002;54:230‐246.
    pubmed: 12062329
  3. Reef VB, Levitan CW, Spencer PA. Factors affecting prognosis and conversion in equine atrial fibrillation.. J Vet Intern Med 1988;2:1‐6.
    pubmed: 3221350
  4. Haugaard MM, Pehrson S, Carstensen H. Antiarrhythmic and electrophysiologic effects of flecainide on acutely induced atrial fibrillation in healthy horses.. J Vet Intern Med 2015;29:339‐347.
    pmc: PMC4858114pubmed: 25328012
  5. Ohmura H, Nukada T, Mizuno Y, Yamaya Y, Nakayama T, Amada A. Safe and efficacious dosage of flecainide acetate for treating equine atrial fibrillation.. J Vet Med Sci 2000;62:711‐715.
    pubmed: 10945288
  6. van Loon G, Blissitt KJ, Keen JA, Young LE. Use of intravenous flecainide in horses with naturally‐occurring atrial fibrillation.. Equine Vet J 2004;36:609‐614.
    pubmed: 15581326
  7. De Clercq D, van Loon G, Baert K. Intravenous amiodarone treatment in horses with chronic atrial fibrillation.. Vet J 2006;172:129‐134.
    pubmed: 15908245
  8. De Clercq D, van Loon G, Baert K. Effects of an adapted intravenous amiodarone treatment protocol in horses with atrial fibrillation.. Equine Vet J 2007;39:344‐349.
    pubmed: 17722727
  9. De Clercq D, van Loon G, Tavernier R, Verbesselt R, Deprez P. Use of propafenone for conversion of chronic atrial fibrillation in horses.. Am J Vet Res 2009;70:223‐227.
    pubmed: 19231955
  10. Broux B, De Clercq D, Decloedt A. Pharmacokinetics and electrophysiological effects of sotalol hydrochloride in horses.. Equine Vet J 2017;50:377‐383.
    pubmed: 29023952
  11. Haugaard MM, Hesselkilde EZ, Pehrson S. Pharmacologic inhibition of small‐conductance calcium‐activated potassium (SK) channels by NS8593 reveals atrial antiarrhythmic potential in horses.. Heart Rhythm 2015;12:825‐835.
    pubmed: 25542425
  12. Carstensen H, Kjaer L, Haugaard MM. Antiarrhythmic effects of combining dofetilide and ranolazine in a model of acutely induced atrial fibrillation in horses.. J Cardiovasc Pharmacol 2018;71:26‐35.
    pmc: PMC5768216pubmed: 29068807
  13. Takahashi Y, Ishikawa Y, Ohmura H. Treatment of recent‐onset atrial fibrillation with quinidine and flecainide in thoroughbred racehorses: 107 cases (1987‐2014).. J Am Vet Med Assoc 2018;252:1409‐1414.
    pubmed: 29772981
  14. Birettoni F, Porciello F, Rishniw M, della Rocca G, Di Salvo A, Sgorbini M. Treatment of chronic atrial fibrillation in the horse with flecainide: personal observation.. Vet Res Commun 2007;31(Suppl 1):273‐275.
    pubmed: 17682893
  15. De Clercq D, van Loon G, Tavernier R, Duchateau L, Deprez P. Atrial and ventricular electrical and contractile remodeling and reverse remodeling owing to short‐term pacing‐induced atrial fibrillation in horses.. J Vet Intern Med 2008;22:1353‐1359.
    pubmed: 19000247
  16. Dembek KA, Hurcombe SD, Schober KE, Toribio RE. Sudden death of a horse with supraventricular tachycardia following oral administration of flecainide acetate.. J Vet Emerg Crit Care (San Antonio) 2014;24:759‐763.
    pubmed: 25388866
  17. Robinson S, Feary D. Sudden death following oral administration of flecainide to horses with naturally occuring atrial fibrillation.. Aust Equine Vet 2008;27:49‐51.
  18. Aliot E, Capucci A, Crijns HJ, Goette A, Tamargo J. Twenty‐five years in the making: flecainide is safe and effective for the management of atrial fibrillation.. Europace 2011;13:161‐173.
    pmc: PMC3024037pubmed: 21138930
  19. January CT, Wann LS, Alpert JS. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society.. Circulation 2014;2014(130):2071‐2104.
    pubmed: 24682348
  20. Buhl R, Ersboll AK, Eriksen L, Koch J. Changes over time in echocardiographic measurements in young Standardbred racehorses undergoing training and racing and association with racing performance.. J Am Vet Med Assoc 2005;226:1881‐1887.
    pubmed: 15934256
  21. Pedersen PJ, Kanters JK, Buhl R, Klaerke DA. Normal electrocardiographic QT interval in race‐fit Standardbred horses at rest and its rate dependence during exercise.. J Vet Cardiol 2013;15:23‐31.
    pubmed: 23434174
  22. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats.. Circulation 1995;92:1954‐1968.
    pubmed: 7671380
  23. Ausma J, Litjens N, Lenders MH. Time course of atrial fibrillation‐induced cellular structural remodeling in atria of the goat.. J Mol Cell Cardiol 2001;33:2083‐2094.
    pubmed: 11735256
  24. McNamara RL, Bass EB, Miller MR. Management of new onset atrial fibrillation.. Evid Rep Technol Assess (Summ) 2000;12:1‐7.
    pmc: PMC4781222pubmed: 11471248
  25. Cosio FG, Aliot E, Botto GL. Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode.. Europace 2008;10:21‐27.
    pubmed: 18086696
  26. Hesselkilde EZ, Carstensen H, Haugaard MM. Effect of flecainide on atrial fibrillatory rate in a large animal model with induced atrial fibrillation.. BMC Cardiovasc Disord 2017;17:289.
    pmc: PMC5723027pubmed: 29221440
  27. Nabar A, Rodriguez LM, Timmermans C, van Mechelen R, Wellens HJ. Class IC antiarrhythmic drug induced atrial flutter: electrocardiographic and electrophysiological findings and their importance for long term outcome after right atrial isthmus ablation.. Heart 2001;85:424‐429.
    pmc: PMC1729704pubmed: 11250970
  28. Crijns HJ, van Gelder IC, Lie KI. Supraventricular tachycardia mimicking ventricular tachycardia during flecainide treatment.. Am J Cardiol 1988;62:1303‐1306.
    pubmed: 3143257
  29. Murdock CJ, Kyles AE, Yeung‐Lai‐Wah JA, Qi A, Vorderbrugge S, Kerr CR. Atrial flutter in patients treated for atrial fibrillation with propafenone.. Am J Cardiol 1990;66:755‐757.
    pubmed: 2399896
  30. Kingma JH, Suttorp MJ. Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, and verapamil.. Am J Cardiol 1992;70:56A‐60A. discussion 60A‐61A.
    pubmed: 1510000
  31. Van Loon G, Jordaens L, Muylle E, Nollet H, Sustronck B. Intracardiac overdrive pacing as a treatment of atrial flutter in a horse.. Vet Rec 1998;142:301‐303.
    pubmed: 9569496
  32. Hudson KB, Brady WJ, Chan TC, Pollack M, Harrigan RA. Electrocardiographic manifestations: ventricular tachycardia.. J Emerg Med 2003;25:303‐314.
    pubmed: 14585460
  33. Goldberger ZD, Rho RW, Page RL. Approach to the diagnosis and initial management of the stable adult patient with a wide complex tachycardia.. Am J Cardiol 2008;101:1456‐1466.
    pubmed: 18471458
  34. Biffi M, Boriani G, Bronzetti G, Capucci A, Branzi A, Magnani B. Electrophysiological effects of flecainide and propafenone on atrial fibrillation cycle and relation with arrhythmia termination.. Heart 1999;82:176‐182.
    pmc: PMC1729125pubmed: 10409531
  35. Hondeghem LM. Antiarrhythmic agents: modulated receptor applications.. Circulation 1987;75:514‐520.
    pubmed: 2434260
  36. Langenfeld H, Kohler C, Weirich J, Kirstein M, Kochsiek K. Reverse use dependence of antiarrhythmic class Ia, Ib, and Ic: effects of drugs on the action potential duration?. Pacing Clin Electrophysiol 1992;15:2097‐2102.
    pubmed: 1279606
  37. Brugada J, Boersma L, Kirchhof C, Allessie M. Proarrhythmic effects of flecainide. Experimental evidence for increased susceptibility to reentrant arrhythmias.. Circulation 1991;84:1808‐1818.
    pubmed: 1914116
  38. Yamashita K, Tsubakishita S, Futaok S. Cardiovascular effects of medetomidine, detomidine and xylazine in horses.. J Vet Med Sci 2000;62:1025‐1032.
    pubmed: 11073071
  39. Valverde A. Alpha‐2 agonists as pain therapy in horses.. Vet Clin North Am Equine Pract 2010;26:515‐532.
    pubmed: 21056297
  40. Gowda RM, Khan IA, Wilbur SL, Vasavada BC, Sacchi TJ. Torsade de pointes: the clinical considerations.. Int J Cardiol 2004;96:1‐6.
    pubmed: 15203254
  41. Nogales Asensio JM, Moreno Sanchez N, Doncel Vecino LJ, Villar Mariscal C, Lopez‐Minguez JR, Merchan Herrera A. Torsade‐de‐pointes in a patient under flecainide treatment, an unusual case of proarrhythmicity.. Int J Cardiol 2007;114:E65‐E67.
    pubmed: 17056139
  42. Hellestrand KJ, Bexton RS, Nathan AW, Spurrell RA, Camm AJ. Acute electrophysiological effects of flecainide acetate on cardiac conduction and refractoriness in man.. Br Heart J 1982;48:140‐148.
    pmc: PMC481218pubmed: 7093083
  43. van Loon G, Fonteyne W, Rottiers H. Dual‐chamber pacemaker implantation via the cephalic vein in healthy equids.. J Vet Intern Med 2001;15:564‐571.
    pubmed: 11817062

Citations

This article has been cited 8 times.
  1. Haugaard SL, Schneider MJ, Kjeldsen ST, Sattler SM, Bastrup JA, Saljic A, Birk JB, Hansen C, Synnestvedt JN, van Hunnik A, Sobota V, Carstensen H, Hopster-Iversen C, Schwarzwald CC, Altintaş A, Barrès R, Jepps TA, Larsen S, Kjøbsted R, Wojtaszewski JFP, Barrado Ballestero S, Roostalu U, Herum KM, Jespersen T, Nattel S, Nissen SD, Buhl R. Metformin Protects Against Persistent Atrial Fibrillation in an Equine Model. Circ Arrhythm Electrophysiol 2025 Dec;18(12):e013850.
    doi: 10.1161/CIRCEP.125.013850pubmed: 41328576google scholar: lookup
  2. Nissen SD, Bastrup JA, Haugaard SL, Marion-Knudsen R, Schneider M, Kjeldsen ST, Carstensen H, Hopster-Iversen C, Nattel S, Jepps TA, Buhl R. Horse model of spontaneous atrial fibrillation share proteomic changes with humans. Sci Rep 2025 Aug 28;15(1):31694.
    doi: 10.1038/s41598-025-16885-7pubmed: 40877415google scholar: lookup
  3. Kuroda T, Minamijima Y, Kinman CK, Takahashi Y, Ebisuda Y, Inoue K, Ishikawa H, Mita H, Tamura N, Nukada T, Toutain PL, Ohta M. Rational quinidine dosage regimen for atrial fibrillation in Thoroughbred racehorses based on population pharmacokinetics. Front Vet Sci 2024;11:1454342.
    doi: 10.3389/fvets.2024.1454342pubmed: 39439824google scholar: lookup
  4. Kjeldsen ST, Nissen SD, Buhl R, Hopster-Iversen C. Paroxysmal Atrial Fibrillation in Horses: Pathophysiology, Diagnostics and Clinical Aspects. Animals (Basel) 2022 Mar 10;12(6).
    doi: 10.3390/ani12060698pubmed: 35327097google scholar: lookup
  5. Fenner MF, Gatta G, Sattler S, Kuiper M, Hesselkilde EM, Adler DMT, Smerup M, Schotten U, Sørensen U, Diness JG, Jespersen T, Verheule S, Van Hunnik A, Buhl R. Inhibition of Small-Conductance Calcium-Activated Potassium Current (I (K,Ca)) Leads to Differential Atrial Electrophysiological Effects in a Horse Model of Persistent Atrial Fibrillation. Front Physiol 2021;12:614483.
    doi: 10.3389/fphys.2021.614483pubmed: 33633584google scholar: lookup
  6. Buhl R, Nissen SD, Winther MLK, Poulsen SK, Hopster-Iversen C, Jespersen T, Sanders P, Carstensen H, Hesselkilde EM. Implantable loop recorders can detect paroxysmal atrial fibrillation in Standardbred racehorses with intermittent poor performance. Equine Vet J 2021 Sep;53(5):955-963.
    doi: 10.1111/evj.13372pubmed: 33113157google scholar: lookup
  7. Fenner MF, Carstensen H, Dalgas Nissen S, Melis Hesselkilde E, Scott Lunddahl C, Adler Hess Jensen M, Loft-Andersen AV, Sattler SM, Platonov P, El-Haou S, Jackson C, Tang R, Kirby R, Ford J, Schotten U, Milnes J, Svane Sørensen U, Jespersen T, Buhl R. Effect of selective I(K,ACh) inhibition by XAF-1407 in an equine model of tachypacing-induced persistent atrial fibrillation. Br J Pharmacol 2020 Aug;177(16):3778-3794.
    doi: 10.1111/bph.15100pubmed: 32436234google scholar: lookup
  8. Hesselkilde EZ, Carstensen H, Flethøj M, Fenner M, Kruse DD, Sattler SM, Tfelt-Hansen J, Pehrson S, Braunstein TH, Carlson J, Platonov PG, Jespersen T, Buhl R. Longitudinal study of electrical, functional and structural remodelling in an equine model of atrial fibrillation. BMC Cardiovasc Disord 2019 Oct 21;19(1):228.
    doi: 10.1186/s12872-019-1210-4pubmed: 31638896google scholar: lookup
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.